Evidence map›Paper›PMID 27286684›Full record

ReviewCancer immunology, immunotherapy : CII2017

Using natural products to promote caspase-8-dependent cancer cell death.

Poonam Tewary, A A Leslie Gunatilaka, Thomas J Sayers

Open access · greenAbstract readReview
In one paragraph

Review in Cancer immunology, immunotherapy : CII, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Evidence-based complementary and alternative medicine : eCAM · 2018
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Poonam TewaryCancer and Inflammation Program, National Cancer Institute, Frederick, Frederick, MD, 21702, USA. tewaryp@mail.nih.gov.
A A Leslie GunatilakaNatural Products Center, School of Natural Resources and the Environment, College of Agriculture and Life Sciences, University of Arizona, Tucson, AZ, USA.
Thomas J SayersCancer and Inflammation Program, National Cancer Institute, Frederick, Frederick, MD, 21702, USA. sayerst@mail.nih.gov.
Frederick National Laboratory for Cancer Research · USNational Cancer Institute · USUniversity of Arizona · US

Funding

Promoting tumor cell apoptosis by death ligandsZIABC011056 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SAYERS, THOMAS · 2009 to 2018
$4.4M
6 · The paper itself

Abstract

The selective killing of cancer cells without toxicity to normal nontransformed cells is an idealized goal of cancer therapy. Thus, there has been much interest in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a protein that appears to selectively kill cancer cells. TRAIL has been reported to trigger apoptosis and under some circumstances, an alternate death signaling pathway termed necroptosis. The relative importance of necroptosis for cell death induction in vivo is under intensive investigation. Nonetheless, many cancer cells (particularly those freshly isolated from cancer patients) are highly resistant to TRAIL-mediated cell death. Therefore, there is an underlying interest in identifying agents that can be combined with TRAIL to improve its efficacy. There are numerous reports in which combination of TRAIL with standard antineoplastic drugs has resulted in enhanced cancer cell death in vitro. However, many of these chemotherapeutic drugs are nonspecific and associated with adverse effects, which raise serious concerns for cancer therapy in patients. By contrast, natural products have been shown to be safer and efficacious alternatives. Recently, a number of studies have suggested that certain natural products when combined with TRAIL can enhance cancer cell death. In this review, we highlight molecular pathways that might be targeted by various natural products to promote cell death, and focus on our recent work with withanolides as TRAIL sensitizers. Finally, we will suggest synergistic approaches for combining active withanolides with various forms of immunotherapy to promote cancer cell death and an effective antitumor immune response.

Indexed as

AnimalsApoptosisBiological ProductsCaspase 8Cell DeathHumansNeoplasmsTNF-Related Apoptosis-Inducing LigandBiological ProductsCaspase 8TNF-Related Apoptosis-Inducing LigandApoptosisNecroptosisPIVAC15Poly (I:C)TRAIL

Identifiers

PMID27286684
PMCPMC11029654
OpenAlexW2418233247

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.